Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2025-12-25 @ 11:18 PM
Study NCT ID:
NCT02501993
Status:
UNKNOWN
Last Update Posted:
2023-07-13
First Post:
2015-07-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Nasopharyngeal Carcinoma Screening in Zhongshan City
Sponsor:
Zhongshan People's Hospital, Guangdong, China
Organization:
Study Overview
Official Title:
Serology Screening Test for the Detection of Nasopharyngeal Carcinoma in Zhongshan City
Status:
UNKNOWN
Status Verified Date:
2023-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to determine the early diagnosis rate and mortality rate of the Nasopharyngeal Carcinoma (NPC) in the study population.
The secondary objective is to determine the incidence of NPC in the study population.
The secondary objective is to determine the incidence of NPC in the study population.
Detailed Description:
The research is to evaluate the effect of NPC screening, also as an extended study of Screening for Nasopharyngeal Carcinoma in High Risk Populations (NCT00941538).
The program was conducted in Xiaolan and Minzhong towns of Zhongshan city in 2012.
All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
The program was conducted in Xiaolan and Minzhong towns of Zhongshan city in 2012.
All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: